tric cancer xenograft, SC-1-NU, transplanted in nude mice.
Materials and methods

Experimental animals and human tumor xenografts
BALB/c male nude mice, obtained from Clea Japan (Tokyo, Japan), were maintained under specific pathogen-free conditions at the Animal Center of the Joint Research Laboratory, Fujita Health University. The human stomach carcinoma xenograft, SC-1-NU (poorly differentiated adenocarcinoma), was serially transplanted in nude mice by inoculating tumor fragments, measuring 3 ϫ 3 ϫ 3mm, subcutaneously in the dorsum of the nude mice, using a trocar needle. SC-1-NU, established at the Second Department of Surgery, Nagoya University School of Medicine, was kindly gifted by Dr. Kubota, at the Department of Surgery, Keio University School of Medicine. SC-1-NU is relatively sensitive to 5-FU [16] . We randomly checked the histological integrity of tumors to ensure that the histology of the tumor was consistently preserved.
Anticancer chemotherapy protocol
The nude mice were assigned to six experimental groups. Eight mice (n ϭ 8) were used for each experimental group. 5-FU was kindly gifted by Kyowa Hakko (Tokyo, Japan). Cisplatin was purchased from Nippon Kayaku (Tokyo, Japan). Each chemotherapeutic regimen is summarized in Fig. 1 . Group A (n ϭ 8) received saline as a control group. Group B (n ϭ 8) received 5-FU (20 mg/kg) daily, 5 days per week. Groups C (n ϭ 8) and E (n ϭ 8) received cisplatin alone; group C received 1.5 mg/kg cisplatin daily on 5 consecutive days per week, and group E received 7.5 mg/kg as a bolus, once per week. Groups D (n ϭ 8) and F (n ϭ 8) received a combination of 5-FU and cisplatin. Group D received 20 mg/kg of 5-FU and 1.5 mg/kg of cisplatin daily, on 5 consecutive days per week. Group F received 20 mg/kg of 5-FU daily on 5 consecutive days per week and 7.5 mg/kg of cisplatin as a bolus, once per week. These chemotherapeutic regimens were performed for either 1 week as a short-term experiment, or for at least 4 weeks as a long-term experiment. After completion of the chemotherapeutic regimens, the mice were killed by cervical dislocation; the tumors were excised immediately and then stored at Ϫ80°C until analyses.
Evaluation of tumor weight, relative tumor weight, and relative tumor-free body weight
The size of the tumor was measured with sliding calipers three times per week by the same observer. The estimated tumor weight (ETW) was calculated using the method described by Geran et al. [17] , that is:
where L is the length and W is the width of the tumor. When the ETW reached 100 to 300 mg, the mice were assigned to the six experimental groups. The relative tumor weight (RTW) was calculated, for the evaluation of the treatments, as follows:
where Wi is the mean ETW at each time point and W0 is the mean ETW at the start of the treatment. The antitumor effects were evaluated by growth curves and the treatment/control (T/C) ratio (%) at the end of the treatment, that is: where RTWt is the mean RTW at the end of the treatment in the treated group and RTWc is the mean RTW in the control group. A positive antitumor effect was defined by the T/C ratio being equal to or less than 0.42, which was derived from the fact that each diameter of the dimension of the tumor regressed less than 75%. The total body weight (TBW) of the mice was also measured, three times per week. The tumor-free body weight (TFBW) was calculated by subtracting the ETW from the TBW. Relative tumor-free body weight was calculated as follows:
where TFBWt is the mean TFBW at the end of the treatment in the treated group and TFBWc is the mean RTW in the control group. When the chemotherapeutic regimens were completed, the mice were killed and the entire tumors were resected within 8 h after the final dose of the agents. The tumors were immediately fixed in paraformaldehyde for 12 h and embedded in paraffin for further analyses.
Calculation of necrosis index
The necrosis index of the tumor was calculated using a histological specimen of the tumor stained by H&E. The necrosis index was defined as the necrotic area as a percentage of the entire tumor area.
Measurement of thymidylate synthase (TS) in tumor tissue
Thymidylate synthase (TS) in tumor tissue was measured by the method originally described by Spears et al. [18, 19] , with some modifications. Briefly, tissue samples (500 mg) were homogenized in citidine monophosphate (CMP) buffer (pH 7.4) containing 2-mercaptoethanol and they were centrifuged to isolate the cytosol fraction of the samples. Then, the cytosol fraction isolated was mixed with 2-mercaptoethanolcontaining buffer at pH 8.1 and incubated at 25°C for 3 h. The samples were mixed with [ ) reaction fluid and the mixture was incubated at room temperature for 20 min. After the addition of dextran coated chacoal (DCC) solution, the radioactivity of the supernatant was measured with a liquid scintillation counter to determine the total TS activity. The TS activity was determined by comparing the radioactivity with those of standard samples. The apparent free TS was measured by mixing the supernatant with 2-mercaptoethanol-containing buffer at pH 8.1, immediately followed by the addition of reaction fluid, without incubation. The apparent free TS was determined by the radioactivity. Free TS was determined as follows:
TS inhibition rate % free TS total TS ( ) ( )
Measurement of DPD in tumor tissue
DPD in tumor tissues was measured using the method described by Diasio et al. [20] . Briefly, the tumor tissues were homogenized with 20 mM phosphate buffer including ethylene diamine tetraacetic acid (EDTA) and 1 mM 2-mercaptoethanol. After centrifugation, an enzyme immunoassay was performed, using 5- H] fluorouracil as a substrate. Dihydrofluorouracil, α-fluoro--uredopropionic acid, and α-fluoro--alanine, derived by an enzyme action, were measured by HPLC. Part of the tissue homogenate was used for the measurement of protein concentration, and the DPD content was expressed as pmol/min per mg protein.
Statistical analysis
Statistical significance was evaluated by Student's t-test. P Ͻ 0.05 was considered statistically significant.
Results
The growth curves of the gastric cancer xenograft during the long-term chemotherapeutic regimen are shown in Fig. 2 . The combined use of 5-FU (20 mg/kg per day) and cisplatin (either 1.5 or 7.5 mg/kg per day) showed a synergistic antitumor effect, regardless of the different doses of cisplatin (Fig. 2) . The growth curves of group D and group F were similar (Fig. 2) ; the T/C ratios 7 days and 25 days after the start of the treatments are summarized in Fig. 3 . Tumor growth was most effectively inhibited with the combined administration of 5-FU and cisplatin, and the lowest T/C ratios, in groups D and F, were apparent at 25 days after the start of the treatment. There was no difference in the T/C ratios between group D and group F at either 7 days or 25 days after the start of the treatment (Fig. 3) .
Changes in the TFBW during the regimens are summarized in Fig. 4 . The TFBW in group D was the lowest for the entire treatment period, but the difference from the other experimental groups was not statistically significant. There was no difference in TFBW during the course of the treatment between any experimental groups.
long-term treatments are summarized in Table 1 . The total TS and the free TS after the short-term treatment were all higher than those after the long-term treatment in all of the experimental groups. The total TS and the percent TS inhibition rate in groups B, D, and F were significantly higher than those in group A after the longterm administration of the anticancer agents.
DPD values after the short-term anticancer chemotherapy are summarized in Table 2 . DPD values in groups B, D, and F (the groups with 5-FU administration, with or without cisplatin) were significantly lower that in group A.
Discussion
The primary aim of the present study was to test whether the synergistic effect of 5-FU with cisplatin was attributable to changes in the percent TS inhibition rate and changes in DPD. The results of the present study demonstrated that the percent TS inhibition rates of 5-FU plus cisplatin were not further increased compared The necrosis indices of each experimental group are shown in Fig. 5 . The necrosis index values after the longterm treatment were all higher than those after the short-term treatments in all of the experimental groups.
Total TS, free TS, and the percent TS inhibition rate of the gastric cancer xenograft after the short-term and with that of 5-FU alone, regardless of the method of administration of cisplatin. While DPD in the shortterm administration of 5-FU was significantly decreased compared with the control value, DPD values in the groups with 5-FU plus cisplatin were not different from that in the group with 5-FU alone. These results suggest that, regardless of whether cisplatin was given as a bolus dose or intermittently, the administration of cisplatin had no effects on TS, TS inhibition, or DPD. Thus, the synergistic anticancer effect of 5-FU with cisplatin may be explained by mechanisms other than an increase in the percent TS inhibition rate and/or DPD. However, it has been reported that the synergistic effect of 5-FU with cisplatin is explained by a further increase in the percent TS inhibition rate. The mechanism responsible for the increase in the TS inhibition rate is reported to be an increase in the 5, 10-methylene tetrahydrofolic acid (CH 2 FH 4 ) pool caused by the decreased methionine uptake induced by cisplatin [10] . This notion is supported by Shirasaka et al. [11] , who demonstrated that a reduced folate pool, of both CH 2 FH 4 and FH 4 , increased after the intraperitoneal administration of cisplatin, in P388 and/or Yoshida sarcoma-bearing rats, in a dose-dependent manner. However, there are no previous studies showing a further increase in the percent TS inhibition rate in treatment with 5-FU plus cisplatin. The results of the present study demonstrated that TS did not further increase in the groups receiving combined administration of 5-FU and cisplatin, regardless of the method of cisplatin administration; this was the first demonstration of changes in TS and percent TS inhibition rates after combined treatment with 5-FU plus cisplatin. Therefore, the synergistic effects of the combination of 5-FU and cisplatin may not be attributable to a further increase in the percent TS inhibition rates. It has been shown that insufficient availability of reduced folate and FdUMP in tumor tissue is an important factor related to the formation of a ternary complex, which is the primary mechanism of TS inhibition. Although reduced folate and FdUMP in tumor tissue after the combined administration of 5-FU and cisplatin were not measured in our study, we cannot rule out the possibility that a further increase in the formation of the ternary complex may have been hampered by the insufficient availability of these factors. The other possibility to explain our findings is inaccuracy of the percent TS inhibition rate data. However, as far as variations of the percent TS inhibition rate data are concerned, the results showing no statistical significance in variations between groups with or without cisplatin would not be caused simply by technical errors of measurement.
Resistance to long-term administration of anticancer agents has been an accepted idea for the oncologist. One of the mechanisms of resistance to 5-FU is an increase in TS, because it has been shown that there are increases in TS after the administration of a 5-FU derivative [21] or cisplatin [22] . Our result showing the increase in TS after the administration of 5-FU was basically consistent with these previous reports. Furthermore, it has recently been reported that high TS protein and/or TS gene expression predicts innate resistance to 5-FU, and such factors are nominated as predictors of poor survival [12, 23, 24] . Recent reports have also demonstrated that chemosensitivity of tumors to 5-FU is correlated with TS protein [12] and/or the expression of TS mRNA [12, 23, 24] . Although it is too early to conclude that TS protein and/or TS mRNA is a good indicator of chemosensitivity of individual tumors, the results of the present study demonstrated an increase TS after the administration of 5-FU, which may be related to resistance to first-line anticancer chemotherapy against gastric carcinoma [25] . Therefore, the increase in TS after the administration of 5-FU shown in the present study may provide some insight into the mechanism of the resistance to 5-FU. The increase in TS could be a good indicator for the timing of a switch from 5-FU-based first-line to a second-line chemotherapeutic agent.
The decrease in DPD in all of the 5-FU-treated groups in our study, regardless of the combined use of cisplatin, was somewhat unexpected, and the reason for the decrease in DPD is unknown. Because DPD is the primary enzyme that metabolizes 5-FU, the induction of DPD as a catabolic enzyme for 5-FU would be expected. There are, however, no reports concerning changes in DPD after the administration of 5-FU and/or cisplatin. Recently, it has been reported that chemosensitivity to 5-FU is correlated with DPD in tumor tissues [13, 26] . Based on these lines of evidence, a DPD inhibitory fluoropyrimidine, S-1, has been developed, and shown to be clinically effective for advanced and recurrent gastric carcinoma [27] . Furthermore, S-1 plus cisplatin has been shown to be one of the most effective combinations for gastric carcinoma [28] , and this regimen has now been widely used as first-line chemotherapy for advanced gastric carcinoma. S-1 contains tegafur, 5-chloro-2,4-dihydroxypyrimidine (CDHP), and oxonate [29] [30] [31] . Tegafur is the prodrug of 5-FU [32, 33] ; thereby, S-1 plus cisplatin basically exerts an anticancer effect through a mechanism that is the same as that underlying the effects of 5-FU plus cisplatin. Although 5-FU combined with cisplatin is still a mainstay as the first-line anticancer chemotherapy for advanced and recurrent gastric carcinoma, repeated doses of this combination result in resistance to these agents, and the mechanism of the resistance remains to be elucidated.
Our study indicated no difference between the groups with low; and high-dose cisplatin plus 5-FU in anticancer effect or side effects, in terms of the changes in tumor-free body weight; thus, administration of low-does cisplatin combined with 5-FU had no clinical advantage over a bolus dose of cisplatin. One of the important benefits of low-dose cisplatin is the reduced incidence of toxic effects [34, 35] , while there is no evidence that suggests that a bolus dose of cisplatin has more potent anticancer effects than a low intermittent dose [34] .
In summary, combined administration of cisplatin with 5-FU did not further increase thymidylate synthase inhibition, which does not support the hypothesis that cisplatin combined with 5-FU modulates thymidylate synthase inhibition in enhancing the anticancer effect of 5-FU. Changes in dihydropyrimidine dehydrogenase after the administration of 5-FU alone and in combination with cisplatin may provide an insight into tumor sensitivity and resistance to 5-FU.
